In The News

Latest News

2
min read

Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer

Halia Presentation and CMO Appointment
Read More
3
min read

Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting

Ofirnoflast ASH 2025 Presentations
Read More
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Press Releases
Jul 16, 2025

Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation

HT-4253 completes Phase 1 NHV Clinical Trial
Read more
Press Releases
Jun 4, 2025

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

Halia Tx Completes MDS Phase 2 Enrollment
Read more
Interviews/ Speaking/ Events
Press Releases
May 28, 2025

Halia Therapeutics CEO Dr. David Bearss to Deliver Keynote Address at Med Investment Forum 2025 in Abu Dhabi

CEO David Bearss to be Keynote speaker at Med Investment Forum 2025 in Abu Dhabi
Read more
Press Releases
Mar 11, 2025

Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research

Halia Tx awarded Novo Nordisk Golden Ticket
Read more